Cosyntropin vs DADLE

Head-to-head comparison of Cosyntropin (Cosyntropin (ACTH 1-24)) and DADLE ([D-Ala2, D-Leu5]-enkephalin) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertyCosyntropinDADLE
CategoryPain ManagementPain Management
Full NameCosyntropin (ACTH 1-24)[D-Ala2, D-Leu5]-enkephalin
Molecular Weight2933.3 Da569.67 Da
Half-Life~10 min5-20 minutes in plasma
Amino Acids245
Typical Dose0.25 mg IV/IM diagnostic dose|off-label headache protocols vary0.01-2 ug per animal
RouteIV|IMIntrathecal / intracerebroventricular
Purity≥98%≥98%
Studies Count61450
Research StatusClinical researchPre-clinical

Cosyntropin Benefits

  • refractory migraine
  • anti-inflammatory signaling
  • headache rescue research

DADLE Benefits

  • delta-opioid agonism
  • enhanced peptide stability
  • spinal analgesia models
  • research on tolerance mechanisms

Cosyntropin Dosing

0.25 mg IV/IM|1 mg IV/IM

DADLE Dosing

Intrathecal 0.01-2 ug per animal|Intracerebroventricular 0.01-1 ug per animal|In vitro 0.1-50 nM

Cosyntropin Side Effects

  • flushing
  • nausea

DADLE Side Effects

  • sedation
  • motor suppression at higher doses
  • opioid tolerance with repeated exposure

Research Overview

Cosyntropin

Cosyntropin is not a standard pain drug, but it appears in headache literature because ACTH analogs can help some patients with difficult migraine attacks. The analgesic rationale is partly tied to steroidogenic and anti-inflammatory effects.

DADLE

DADLE has been studied for analgesic, neuroprotective, and receptor-selective opioid effects in animal and tissue models. It remains important as a mechanistic probe because it is more stable than endogenous enkephalins but still peptide-like in its delivery constraints.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

Cosyntropin stacks with:

ACTH(1-24)Synacthen

DADLE stacks with:

morphineketamine
migraineheadacheACTH-analogenkephalin-analogdelta-opioidanalgesiapeptide-therapeutic